Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (5): 705-712    DOI: 10.31083/j.ejgo.2020.05.5448
Original Research Previous articles | Next articles
Sequential Chemoradiation versus Radiation for the Adjuvant Treatment of Stage III Endometrioid Adenocarcinoma of the Uterus
Yu Hui Lim1, *(), Sheow Lei Lim1, Linda Xiao Hui Lin1, Lay Tin Soh2, Hoon Seng Khoo Tan2, Richard Ming Chert Yeo2, Timothy Yong Kuei Lim1
1Department of Gynaecological Oncology, KK Women's and Children's Hospital, Singapore
2National Cancer Centre, Singapore
Download:  PDF(212KB)  ( 187 ) Full text   ( 6 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose of Investigation: The optimal adjuvant therapy for women with Stage III endometrial cancer following surgical staging is controversial. Post-operative sequential chemotherapy followed by external beam radiotherapy is the standard treatment for Stage III uterine cancer at our institution since 2006. We aim to analyse the survival outcomes in this group of patients comparing with the historical group of patients who received radiation only. Materials and Methods: This is a retrospective single-institution analysis of patients with surgical Stage III endometrioid adenocarcinoma of the uterus treated at KK Women's and Children's Hospital from 2000 to 2010. Results: Ninety-six patients with surgical Stage III endometrioid endometrial cancer who received postoperative adjuvant therapies were identified; 43% (n = 41) received chemotherapy followed by radiotherapy, 57% (n = 55) received radiotherapy only. The 2 groups were well balanced with regard to age, ECOG performance status, tumour size, myometrial invasion, lymphovascular invasion, peritoneal cytology status and debulking status. At a median follow up of 62.5 months (range: 4 -164), the 5-year overall survival (OS), cancer-specific survival (CSS) and disease-free survival (DFS) were not significantly different. Following adjustment for age, disease stage, tumour grade, residual disease, tumour size and nodal status, the adjusted hazard ratios for DFS, CSS and OS for those treated with chemoradiation were not significantly better than those treated with radiation only. Conclusion: In this single institution retrospective analysis of Asian patients with surgical Stage III endometrioid endometrial cancer, there was a trend towards sequential chemotherapy followed by radiation having better OS and CSS over radiation alone but this did not reach statistical significance.
Key words:  Endometrial cancer      Chemotherapy      Radiotherapy     
Submitted:  16 October 2019      Accepted:  17 April 2020      Published:  15 October 2020     
*Corresponding Author(s):  YU HUI LIM     E-mail:  lim.yu.hui@singhealth.com.sg

Cite this article: 

Yu Hui Lim, Sheow Lei Lim, Linda Xiao Hui Lin, Lay Tin Soh, Hoon Seng Khoo Tan, Richard Ming Chert Yeo, Timothy Yong Kuei Lim. Sequential Chemoradiation versus Radiation for the Adjuvant Treatment of Stage III Endometrioid Adenocarcinoma of the Uterus. European Journal of Gynaecological Oncology, 2020, 41(5): 705-712.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.05.5448     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I5/705

[1] Ikuji Shimazaki, Yasunori Hashiguchi, Makoto Yamauchi, Mari Kasai, Takeshi Fukuda, Tomoyuki Ichimura, Tomoyo Yasui, Toshiyuki Sumi. Secondary small cell vaginal cancer after operative therapy for endometrial cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 821-823.
[2] Eda Kucuktulu, Ahmet Fatih Yurekli. Simultaneous Integrated Intensity Modulated Radiotherapy Boost for Gynecological Cancer when Brachytherapy is not an Option[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 720-725.
[3] Yanan Li, Dongge Wang, Xiaodong Li, Wangchao Zhang, Xianghua Huang, Yibin Liu. Appendix invasion of squamous cell carcinoma arising from ovarian mature cystic teratoma and resistant to combination chemotherapy with docetaxel and oxaliplatin: a case report[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 841-844.
[4] Yan qin Zhang, Di Wu, Meng qi Deng, Xiang yu Chang, Jin wei Miao, Yu mei Wu. Individual management of cervical cancer during pregnancy[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 833-837.
[5] Michelle F. Benoit, Kristy K. Ward. Uterine Cancer Normogram to Predict Lymph Node Metastasis: Comparison to the Mayo Algorithm and an External Validation of a Model in a North American Population[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 681-684.
[6] Joseph J. Noh, Sir-Yeon Hong, Byeong-gie Kim. Malignant perivascular epithelioid cell tumor (PEComa) of uterus: A case report with literature review[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 495-499.
[7] Yusuf Cakmak, Tufan Oge. The effect of age on prediction of concurrent endometrial cancer in patients with atypical endometrial hyperplasia[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 531-535.
[8] Krittiya Somaketarin, Charuwan Tantipalakorn, Kittipat Charoenkwan, Prapaporn Suprasert, Jatupol Srisomboon. Survival outcomes of sex cord-stromal tumors of the ovary[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 563-568.
[9] Sigit Purbadi, Gregorius Tanamas, Lisa Novianti. Advanced stage ovarian cancer survival in Jakarta[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 587-590.
[10] Di Wu, Jirui Zhang, Chengxi Yang. Effect of letrozole combined with testosterone on the proliferation and apoptosis of endometrial carcinoma cells[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 604-608.
[11] Hikari Unno, Seiji Mabuchi, Isao Arai, Tomoko Wakasa, Seiichi Yamamasu. Development of lymphangiosarcoma after pelvic radiation therapy for uterine cervical cancer: A case report and literature review[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 326-331.
[12] B.-H. Zhang, L. Li, J. Ji, J. Guo, X.-L. Zhou, H. Xu, F. Cao, X.-H. Tong. Prognostic value of Foxp3+ regulatory T cells in endometrial cancer: a meta-analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 339-342.
[13] T. Shoji, E. Takatori, M. Kagabu, M. Futagami, Y. Yokoyama, H. Tokunaga, N. Yaegashi, T. Ohta, T. Watanabe, T Sugiyama. Relationship between usefulness of irinotecan and pegylated liposomal doxorubicin therapy and the UGT1A1 genotype in patients with recurrent ovarian cancer (TGCU 104 study)[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 380-385.
[14] H. Ishibashi, M. Miyamoto, T. Aoyama, H. Soyama, H. Matsuura, H. Iwahashi, M. Takano, K. Furuya. The effect of six scheduled cycles of neoadjuvant chemotherapy on prognosis in advanced ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 386-390.
[15] J.Y. Chen, Z.Q. Wang, S.C. Liang, H.Y. Hou, D.B. Chen, J.L. Wang. Sentinel lymph node mapping with carbon nanoparticles in endometrial cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 408-414.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] B. Soltész, J. Lukács, A. Penyige, R. Póka, B. Nagy. Determination of miR-193b rs30236 single nucleotide polymorphism in ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 547 -550 .
[3] Y. Li, C. Li, N. Li, L. Jiang, W. Yang, Y. Wang, B. Wu, C. Shi, Z. Zhu. RNAi silenced NUP88 gene suppresses growth and invasiveness of human breast cancer cell line MCF-7[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 634 -639 .
[4] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781 -786 .
[5] T. Tomimatsu, S. Mabuchi, T. Tsuboyama, Y. Hori, S. Sekine, T. Kimura. Malignant transformation of uterine leiomyoma: suggested by clinical, imaging, histological, and genetic findings[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 879 -882 .
[6] T. Ueno, H. Yabushita, K. Iwasaki, A. Wakatsuki. Role of adiponectin and leptin in non-diabetic, non-obese patients with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 199 -204 .
[7] P. Pimsi, W. Santimaleeworagun, S. Therasakvichya, N. Saengsukkasemsak, A. Laocharoenkeat. The incidence and risk factors of severe neutropenia and febrile neutropenia due to chemotherapy among gynecologic cancer patients in Thailand[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 242 -246 .
[8] F. Lai-Tiong. Dermatomyositis revealing a 18-year breast cancer recurrence[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 292 -293 .
[9] M.F. Benoit, K.A. O'Hanlan, M.S. Sten, C.L. Kosnik, D.M. Struck, M.S. O'Holleran, J. Cuff, D.M. Halliday, E.A. Kent. Incidental appendectomy at the time of gynecologic surgery[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 386 -389 .
[10] E. Yilmaz, E. I. Coskun, C. Koc, N. Sahin, B. Isik, B. Ciplak. Isolated recurrence of early-stage cervical cancer in the abdominal wall with suboptimal surgery[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 485 -487 .